(VIANEWS) – MONTEA (MONT.BR), PERRIER (GERARD) (PERR.PA), BOIRON (BOI.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MONTEA (MONT.BR)
25.8% sales growth and 17.64% return on equity
Montea is a developing investor in logistics real estate in Belgium, France, Germany and the Netherlands. Our team of passionate specialists creates the ideal real estate solution together with the customer.
Earnings Per Share
As for profitability, MONTEA has a trailing twelve months EPS of €9.74.
PE Ratio
MONTEA has a trailing twelve months price to earnings ratio of 7.8. Meaning, the purchaser of the share is investing €7.8 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.64%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 26.3%, now sitting on 111.01M for the twelve trailing months.
Yearly Top and Bottom Value
MONTEA’s stock is valued at €76.00 at 11:20 EST, way below its 52-week high of €123.20 and way above its 52-week low of €62.20.
2. PERRIER (GERARD) (PERR.PA)
19.8% sales growth and 17.05% return on equity
Gérard Perrier Industrie S.A. engages in designing, manufacturing, installing, and maintaining of electrical, electronic, automation, and instrumentation equipment in France and internationally. It engages in the engineering, installation, and maintenance of HV/LV distribution networks, electric drive systems, low current systems, lighting products, electric boxes, cabinets, and modules. The company is also involved in the study, manufacture, and installation of electronic boards, modules, sub-assemblies, assemblies, man-machine interfaces for on-board systems, built-in automated and electronic systems, switched-mode power supplies and converters for on-board systems, and variators and engine control systems; study, engineering, and maintenance of automation projects; and design, analysis, and programming of techniques for automation supervision and MES systems. In addition, it manufactures sub-assemblies, such as electronic, electro-technical, assembly of mechanical, and fluid and pneumatic modules; implements engineering projects in the oil and gas, nuclear, and military sectors; and technical assistance for various businesses, such as mechanics, valves, boiler-making, civil engineering, and non-destructive testing. The company was founded in 1967 and is headquartered in Lyon, France. Gérard Perrier Industrie S.A. is a subsidiary of Amperra SAS.
Earnings Per Share
As for profitability, PERRIER (GERARD) has a trailing twelve months EPS of €4.2.
PE Ratio
PERRIER (GERARD) has a trailing twelve months price to earnings ratio of 22.71. Meaning, the purchaser of the share is investing €22.71 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.05%.
Yearly Top and Bottom Value
PERRIER (GERARD)’s stock is valued at €95.40 at 11:20 EST, below its 52-week high of €102.50 and way above its 52-week low of €79.20.
Volume
Today’s last reported volume for PERRIER (GERARD) is 140 which is 81.1% below its average volume of 741.
3. BOIRON (BOI.PA)
17.3% sales growth and 9.87% return on equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.86.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 14.3. Meaning, the purchaser of the share is investing €14.3 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.87%.
Volume
Today’s last reported volume for BOIRON is 738 which is 88.93% below its average volume of 6671.
4. ALTRI SGPS (ALTR.LS)
16% sales growth and 24.22% return on equity
Altri, SGPS, S.A. produces and sells bleached eucalyptus pulp in Portugal and internationally. It offers bleached eucalyptus kraft pulp for use in a range of papers, such as tissues, and printing and writing papers; and dissolving pulp for use in textile production. The company is also involved timber commercialization; forest management; the production of energy from forest resources, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. The company was incorporated in 2005 and is headquartered in Porto, Portugal.
Earnings Per Share
As for profitability, ALTRI SGPS has a trailing twelve months EPS of €0.17.
PE Ratio
ALTRI SGPS has a trailing twelve months price to earnings ratio of 27.16. Meaning, the purchaser of the share is investing €27.16 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.22%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ALTRI SGPS’s EBITDA is 15.43.
Yearly Top and Bottom Value
ALTRI SGPS’s stock is valued at €4.62 at 11:20 EST, way below its 52-week high of €6.83 and above its 52-week low of €4.50.
Moving Average
ALTRI SGPS’s value is below its 50-day moving average of €4.82 and way under its 200-day moving average of €5.48.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 52.9% and 50%, respectively.
